Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Steven Knapper

Has grant

Professor in Haematology

Cardiff University

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom Professors in Immunology Immunology professors in United Kingdom

Recent Grants

Grant: Open

Optimise-FLT3 Study: Optimising therapy for patients with FLT3-mutated Acute Myeloid Leukaemia

Open Date: 2024-03-01

Close Date: 2031-02-01

Grant: Open

Cardiff Experimental Cancer Medicine Centre

Open Date: 2023-04-01

Close Date: 2028-03-01

Grant: Close

Molecular characterisation of patients with NPM1-mutated AML who enter deep remission without intensive chemotherapy: scientific correlates of the VICTOR trial. 2021-2023

Open Date: 2021-01-01

Close Date: 2023-01-01

Grant: Close

Trials Acceleration Programme Centre Funding

Open Date: 2020-01-01

Close Date: 2023-01-01

Grant: Close

VICTOR: Venetoclax or intensive chemotherapy for treatment of favourable risk acute myeloid leukaemia: a molecularly-guided phase 2 study.

Open Date: 2020-01-01

Close Date: 2025-01-01

Articles (20)

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (33)

Richard Dillon

King's College

UNITED KINGDOM

View details

Henry Wood

King's College Hospital NHS Foundation Trust

UNITED KINGDOM

View details

Ariel Wang

University of Oxford

UNITED KINGDOM

View details

Puja mehta

Assistant Professor of Medicine

University College London

UNITED KINGDOM

View details

Jenny O'Nions

UNITED KINGDOM

View details

Robert Hills

Professor of Medical Statistics

University of Oxford

UNITED KINGDOM

View details

Elie Traer

Oregon Health & Science University

UNITED STATES

View details

Nicholas Cross

Professor of Human Genetics

University of Southampton

UNITED KINGDOM

View details

Bethan Psaila

University of Oxford

UNITED KINGDOM

View details

Christian Ottensmeier

Professor of Immuno-Oncology

University of Liverpool

UNITED KINGDOM

View details

David M. Lowe

UNITED KINGDOM

View details

Kimmo Porkka

University of Helsinki

FINLAND

View details

Matthew Bashton

Assistant Professor

Northumbria University

UNITED KINGDOM

View details

Sian Griffin

Consultant and Honorary Professor

Cardiff and Vale University Health Board

UNITED KINGDOM

View details

Steven Lane

LAB HEAD

QIMR Berghofer Medical Research Institute

AUSTRALIA

View details

Lisette Nixon

Senior Research Fellow; Deputy Head of Trial Management (Cancer)

Cardiff University

UNITED KINGDOM

View details

Richard Adams

Professor

Cardiff University

UNITED KINGDOM

View details

Mika Kontro

Group Leader

University of Helsinki

FINLAND

View details

Charlotte Brierley

Academic Clinical Lecturer

University of Oxford

UNITED KINGDOM

View details

Niels Asger Jakobsen

University of Oxford

UNITED KINGDOM

View details

Dorian Forte

Assistant Professor (junior)

University of Bologna

ITALY

View details

Eleanor Barnes

Professor of Hepatology and Experimental Medicine

University of Oxford

UNITED KINGDOM

View details

Adam Mead

University of Oxford

UNITED KINGDOM

View details

Joseph Hamley

University of Oxford

UNITED KINGDOM

View details

Bob Löwenberg

Erasmus University Rotterdam

NETHERLANDS

View details

Marianne Tang Severinsen

Aalborg University

DENMARK

View details

Thomas Pabst

Professor

University Hospital of Bern

SWITZERLAND

View details

Amir Enshaei

Senior Lecturer

Newcastle University

UNITED KINGDOM

View details

Paresh Vyas

University of Oxford

UNITED KINGDOM

View details

Sylvie Freeman

University of Birmingham

UNITED KINGDOM

View details

Jurgen Kuball

UMC Utrecht

NETHERLANDS

View details

Justin Loke

Cancer Research UK Manchester Institute

UNITED KINGDOM

View details

Nina Orfali

Trinity College Dublin, The University of Dublin

IRELAND

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Steven Knapper

Research Interests

Explore related searches

Recent Grants

Articles (20)

Combining Quizartinib with intensive chemotherapy in older patients with newly diagnosed AML: results of the UK NCRI AML18 Trial

CPX-351 vs daunorubicin, cytarabine, and gemtuzumab ozogamicin in older adults with non–adverse-risk AML: the NCRI AML18 trial

Venetoclax‐based non‐intensive combinations for relapsed/refractory acute myeloid leukaemia—Real‐world data from a UK‐wide programme

A revised prognostic model for patients with acute myeloid leukemia and first relapse

Chromothripsis-associated chromosome 21 amplification orchestrates transformation to blast-phase MPN through targetable overexpression of DYRK1A

Adaptive clinical trial of AZD7442 and SARS-CoV-2 vaccination in immunosuppressed patients highly vulnerable to infection with SARS-CoV-2 virus (RAPID-PROTECTION): protocol for a multicentre, interventional open-label, randomised controlled trial

Molecular monitoring versus standard clinical care in younger adults with acute myeloid leukaemia: results from the UK NCRI AML17 and AML19 randomised, controlled, phase 3 trials.

Risk Stratification in Older Intensively Treated Patients With AML

The management of myelofibrosis: A British Society for Haematology Guideline

Treatment Intensification With Either Fludarabine, AraC, G-CSF and Idarubicin, or Cladribine Plus Daunorubicin and AraC on the Basis of Residual Disease Status in Older Patients With AML: Results From the NCRI AML18 Trial

Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With <i>NPM1</i> and <i>FLT3</i> Mutations.

Venetoclax-based low intensity therapy in molecular failure of NPM1-mutated AML

FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML

Fractionated Versus Single Dose Gemtuzumab Ozogamicin with Determinants of Benefit in Older AML: UK NCRI AML18 Trial

Defective T‐cell response to COVID‐19 vaccination in acute myeloid leukaemia and myelodysplastic syndromes

A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial

Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes

Characteristics and outcomes of patients with acute promyelocytic leukemia and extreme hyperleukocytosis at presentation

Tamoxifen for the treatment of myeloproliferative neoplasms: A Phase II clinical trial and exploratory analysis

Diagnosis and evaluation of prognosis of myelofibrosis: A British Society for Haematology Guideline.

Collaborators (33)

Richard Dillon

Henry Wood

Ariel Wang

Puja mehta

Jenny O'Nions

Robert Hills

Elie Traer

Nicholas Cross

Bethan Psaila

Christian Ottensmeier

David M. Lowe

Kimmo Porkka

Matthew Bashton

Sian Griffin

Steven Lane

Lisette Nixon

Richard Adams

Mika Kontro

Charlotte Brierley

Niels Asger Jakobsen

Dorian Forte

Eleanor Barnes

Adam Mead

Joseph Hamley

Bob Löwenberg

Marianne Tang Severinsen

Thomas Pabst

Amir Enshaei

Paresh Vyas

Sylvie Freeman

Jurgen Kuball

Justin Loke

Nina Orfali

Make your next move.